Bioequivalence requirements for generic products
- 31 December 1994
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 62 (1-2), 41-55
- https://doi.org/10.1016/0163-7258(94)90004-3
Abstract
Many countries have established procedures for the introduction of generic pharmaceutical products. In order to protect consumers, these generic products must be demonstrated to be therapeutically equivalent to a previously approved product, typically an innovator product. The therapeutic equivalence of a generic and an innovator product is most commonly based on the demonstrated of bioequivalence, i.e. clinically insignificant differences in the rate and extent of drug absorption usually assessed from pharmacokinetic measurements. This article reviews the bioequivalence requirements for generic products and, in the interest of promoting international harmonisation, highlights those areas where differences exist among countries.Keywords
This publication has 20 references indexed in Scilit:
- Enantioselective versus non‐enantioselective assays in comparative bioavailability studies with racemic drugsBiopharmaceutics & Drug Disposition, 1992
- Enantioselective versus non‐enantioselective assays in comparative bioavailability studies with racemic drugsBiopharmaceutics & Drug Disposition, 1992
- Pharmacodynamics as a tool to assess the bioequivalence of nonystemically available drugs: Size of the sample requiredBiopharmaceutics & Drug Disposition, 1992
- Genetic Aspects of Drug Disposition and TherapeuticsThe Journal of Clinical Pharmacology, 1992
- Interactions with oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 1990
- Enantioselective Aspects of Drug Action and Disposition: Therapeutic PitfallsJournal of Pharmaceutical Sciences, 1989
- Stereoselective drug disposition: potential for misinterpretation of drug disposition data.British Journal of Clinical Pharmacology, 1988
- Application of a Stereospecific High-Performance Liquid Chromatography Assay to a Pharmacokinetic Study of Etodolac Enantiomers in HumansJournal of Pharmaceutical Sciences, 1988
- Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overviewCancer Cell, 1986
- Pharmacokinetic Determinants in the Design and Evaluation of Sustained-Release Dosage FormsPharmaceutical Research, 1984